CTXR Citius Pharmaceuticals Inc.

0.71
-0.08  -10%
Previous Close 0.79
Open 0.77
Price To Book 1.25
Market Cap 25,573,963
Shares 35,918,487
Volume 287,108
Short Ratio
Av. Daily Volume 729,273
Stock charts supplied by TradingView

NewsSee all news

  1. Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference

    CRANFORD, N.J., Feb. 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  2. Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok®

    CRANFORD, N.J., Feb. 25, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  3. Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference

    CRANFORD, N.J., Feb. 10, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  4. Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

    CRANFORD, N.J., Feb. 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical-care

  5. Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

    CRANFORD, N.J., Feb. 3, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 75% interim analysis for superior efficacy expected 1H 2020.
Mino-Lok
Catheter related blood stream infection
Phase 2b trial planned for 2020.
CITI-002
Hemorrhoids

Latest News

  1. Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference

    CRANFORD, N.J., Feb. 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  2. Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok®

    CRANFORD, N.J., Feb. 25, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  3. Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference

    CRANFORD, N.J., Feb. 10, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  4. Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

    CRANFORD, N.J., Feb. 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical-care

  5. Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

    CRANFORD, N.J., Feb. 3, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  6. Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses

    Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks releases a special

  7. Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial

    CRANFORD, N.J., Dec. 19, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  8. Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event

    CRANFORD, N.J., Dec. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  9. Citius Pharmaceuticals Issues Corporate Update

    CRANFORD, N.J., Nov. 8, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:  CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on adjunctive cancer care and critical

  10. Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference

    CRANFORD, N.J., Oct. 24, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on developing adjunctive cancer care and

  11. MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  12. Citius Pharmaceuticals to Present at the MicroCap Rodeo

    CRANFORD, N.J., Oct. 15, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug

  13. Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial

    CRANFORD, N.J., Oct. 7, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug

  14. Citius Provides Update on Activities From IDWeek 2019

    CRANFORD, N.J., Oct. 3, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug

  15. Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Sept. 27, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  16. Citius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market

    CRANFORD, N.J., Sept. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care

  17. Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study

    CRANFORD, N.J., Sept. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug

  18. Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.

    CRANFORD, N.J., Aug. 29, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced